Results 41 to 50 of about 14,427,656 (303)

Hepatitis B Virus Reactivation with Discontinuation of Nucleoside Analogue in Patients Who Received Allogeneic Hematopoietic Stem Cell Transplantation

open access: yesCase Reports in Gastroenterology, 2021
Reactivation of hepatitis B virus (HBV) is known to occur frequently after hematopoietic stem cell transplantation (HSCT). The reactivation can be prevented by nucleos(t)ide analogue (NA), but it is unclear how long NA should be continued.
Mio Tsuruoka   +9 more
doaj   +1 more source

Virus-like Vesicles Expressing Multiple Antigens for Immunotherapy of Chronic Hepatitis B

open access: yesiScience, 2019
Summary: Infections with hepatitis B virus (HBV) can initiate chronic hepatitis and liver injury, causing more than 600,000 deaths each year worldwide.
Timur O. Yarovinsky   +13 more
doaj   +1 more source

Hepatitis B Core Antigen: Immunology and Electron Microscopy [PDF]

open access: yesJournal of Virology, 1974
Two distinct viral antigens are associated with the hepatitis B virus: the hepatitis B surface antigen (HB s Ag, Australia antigen) and the hepatitis B core antigen (HB c Ag). HB s Ag, purified from the serum of asymptomatic human HB s Ag ...
L F, Barker   +5 more
openaire   +2 more sources

Viral Hepatitis and Rapid Diagnostic Test Based Screening for HBsAg in HIV-infected Patients in Rural Tanzania. [PDF]

open access: yes, 2013
\ud \ud Co-infection with hepatitis B virus (HBV) is highly prevalent in people living with HIV in Sub-Saharan Africa. Screening for HBV surface antigen (HBsAg) before initiation of combination antiretroviral therapy (cART) is recommended. However, it is
Emilio Letang   +34 more
core   +2 more sources

Demonstration of the Immunogenicity of Hepatitis B Core Antigen in a Hepatitis B e Antigen Polypeptide (P19)

open access: yesJournal of General Virology, 1981
The core of Dane particles, the presently accepted hepatitis B virus nucleocapsid, contains two polypeptides (P19 and P45) with the antigenicity of hepatitis B e antigen (HBeAg). The antigenicity of hepatitis B core antigen (HBcAg) was not detectable in either of them by the conventional in vitro assay methods, despite the fact that both of these ...
K, Takahashi   +7 more
openaire   +2 more sources

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

open access: yes, 2022
Hepatology, EarlyView.
Robert J. Fontana   +6 more
wiley   +1 more source

Transcriptional profiling of circulating extracellular vesicles from prebiopsy prostate cancer patients

open access: yesMolecular Oncology, EarlyView.
RNA profiling of circulating extracellular vesicles (EVs) from blood samples of men undergoing prostate biopsy identifies transcripts associated with clinically significant prostate cancer. Integrative analysis with public tumor datasets links EV‐derived gene signatures to tumor stage and progression‐free survival, highlighting CASP3, XRCC2, and RIT1 ...
Stefan Werner   +14 more
wiley   +1 more source

Chronobiology of Cancer: How Aging Fuels Oncogenesis at the Molecular Level

open access: yesAging and Cancer, EarlyView.
This graphical abstract illustrates the key biological pathways linking aging with cancer development and progression. In the upper left, cumulative exposure to ultraviolet radiation, toxins, and reactive oxygen species (ROS) causes DNA damage and genomic instability, whereas age‐related decline in repair mechanisms, such as ATM/ATR, BER, and NER ...
Anu Singh, Aroonima Misra, Sufian Zaheer
wiley   +1 more source

Diversity of core antigen epitopes of hepatitis B virus [PDF]

open access: yesProceedings of the National Academy of Sciences, 2003
Core antigen (cAg), the viral capsid, is one of the three major clinical antigens of hepatitis B virus. cAg has been described as presenting either one or two conformational epitopes involving the “immunodominant loop.” We have investigated cAg antigenicity by cryo-electron microscopy at ≈11-Å resolution of capsids labeled with monoclonal Fabs ...
D M, Belnap   +6 more
openaire   +2 more sources

Inebilizumab in AQP4‐Seropositive NMOSD: One‐Year Follow‐Up From a Multicenter, Real‐World Study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Real‐world evidence on inebilizumab among neuromyelitis optica spectrum disorder (NMOSD) patients is lacking. This study assessed inebilizumab among Chinese patients with aquaporin 4 autoantibody (AQP4‐IgG)‐seropositive NMOSD in a real‐world setting.
Mengcui Gui   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy